[{"address1": "4660 La Jolla Village Drive", "address2": "Suite 100", "city": "San Diego", "state": "CA", "zip": "92122", "country": "United States", "phone": "650 800 3717", "website": "https://www.revbiosciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Mr. James M. Rolke", "age": 54, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 649250, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chester Stanley Zygmont III", "age": 43, "title": "CFO & Corporate Secretary", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 479141, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sandra  Vedrick", "title": "Vice President of Human Resources & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Carol  Odle", "title": "Senior Director of Clinical Projects", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.84, "open": 0.825, "dayLow": 0.825, "dayHigh": 0.86, "regularMarketPreviousClose": 0.84, "regularMarketOpen": 0.825, "regularMarketDayLow": 0.825, "regularMarketDayHigh": 0.86, "beta": 0.181, "forwardPE": -0.15008993, "volume": 39657, "regularMarketVolume": 39657, "averageVolume": 1614990, "averageVolume10days": 78110, "averageDailyVolume10Day": 78110, "marketCap": 3194349, "fiftyTwoWeekLow": 0.702, "fiftyTwoWeekHigh": 25.26, "fiftyDayAverage": 0.9243, "twoHundredDayAverage": 2.558645, "currency": "USD", "enterpriseValue": -10701645, "floatShares": 1638038, "sharesOutstanding": 3758060, "sharesShort": 22746, "sharesShortPriorMonth": 25650, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0061000003, "heldPercentInsiders": 0.00141, "heldPercentInstitutions": 0.01347, "shortRatio": 0.13, "shortPercentOfFloat": 0.0061000003, "impliedSharesOutstanding": 3827860, "bookValue": 0.694, "priceToBook": 1.2024496, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -15902531, "trailingEps": -33.18, "forwardEps": -5.56, "lastSplitFactor": "1:30", "lastSplitDate": 1706140800, "enterpriseToEbitda": 1.126, "52WeekChange": -0.9520941, "SandP52WeekChange": 0.39389753, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "REVB", "underlyingSymbol": "REVB", "shortName": "Revelation Biosciences, Inc.", "longName": "Revelation Biosciences, Inc.", "firstTradeDateEpochUtc": 1605623400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f994477e-3690-3dde-965e-6f9faa0f03d6", "messageBoardId": "finmb_696222591", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.8345, "targetHighPrice": 20.0, "targetLowPrice": 8.9, "targetMeanPrice": 14.45, "targetMedianPrice": 14.45, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 12073058, "totalCashPerShare": 7.346, "ebitda": -9502316, "quickRatio": 1.085, "currentRatio": 1.096, "returnOnAssets": -0.42074, "returnOnEquity": -2.53321, "freeCashflow": 834401, "operatingCashflow": -9036168, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-28"}]